Minjie Wei

14.0k total citations · 2 hit papers
153 papers, 4.7k citations indexed

About

Minjie Wei is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Minjie Wei has authored 153 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Molecular Biology, 61 papers in Cancer Research and 43 papers in Oncology. Recurrent topics in Minjie Wei's work include RNA modifications and cancer (36 papers), Cancer-related molecular mechanisms research (33 papers) and Ferroptosis and cancer prognosis (24 papers). Minjie Wei is often cited by papers focused on RNA modifications and cancer (36 papers), Cancer-related molecular mechanisms research (33 papers) and Ferroptosis and cancer prognosis (24 papers). Minjie Wei collaborates with scholars based in China, United States and Saint Kitts and Nevis. Minjie Wei's co-authors include Lin Zhao, Miao He, Bin Ji, Bin Yang, Huizhe Wu, Longyang Jiang, Zhaojin Yu, Yuanyuan Yan, Weifan Yao and Yan Wang and has published in prestigious journals such as Blood, PLoS ONE and Oncogene.

In The Last Decade

Minjie Wei

149 papers receiving 4.6k citations

Hit Papers

Recent advances in nanomedicines for photodynamic therapy... 2021 2026 2022 2024 2021 2022 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Minjie Wei China 38 3.1k 2.0k 1.1k 743 546 153 4.7k
Kangsheng Tu China 43 3.5k 1.1× 2.4k 1.2× 719 0.6× 422 0.6× 377 0.7× 110 5.4k
Hongping Xia China 37 3.2k 1.0× 2.4k 1.2× 683 0.6× 604 0.8× 327 0.6× 97 4.5k
Chang Zou China 33 2.1k 0.7× 1.1k 0.5× 997 0.9× 547 0.7× 499 0.9× 120 3.9k
Guoguang Ying China 36 4.0k 1.3× 2.7k 1.3× 759 0.7× 692 0.9× 590 1.1× 88 5.1k
Bin Xiong China 32 1.9k 0.6× 1.3k 0.6× 1.6k 1.4× 637 0.9× 729 1.3× 99 4.1k
Weiling He China 31 1.9k 0.6× 1.2k 0.6× 877 0.8× 473 0.6× 557 1.0× 94 3.7k
Jie Hu China 32 2.2k 0.7× 1.8k 0.9× 989 0.9× 700 0.9× 585 1.1× 134 4.3k
Minghui Wang China 32 2.2k 0.7× 1.4k 0.7× 1.0k 0.9× 599 0.8× 521 1.0× 137 3.9k
Wei‐Zhong Wu China 41 3.5k 1.1× 1.9k 0.9× 2.1k 1.9× 470 0.6× 1.0k 1.9× 107 5.7k

Countries citing papers authored by Minjie Wei

Since Specialization
Citations

This map shows the geographic impact of Minjie Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minjie Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minjie Wei more than expected).

Fields of papers citing papers by Minjie Wei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minjie Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minjie Wei. The network helps show where Minjie Wei may publish in the future.

Co-authorship network of co-authors of Minjie Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Minjie Wei. A scholar is included among the top collaborators of Minjie Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minjie Wei. Minjie Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Ting, Ying‐Qi Zhao, Xinming Zhang, et al.. (2025). Short‐chain acyl post‐translational modifications in cancers: Mechanisms, roles, and therapeutic implications. Cancer Communications. 45(10). 1247–1284. 17 indexed citations
2.
Li, Yunong, et al.. (2024). Chiral inorganic nanomaterials in the tumor microenvironment: A new chapter in cancer therapy. Pharmacological Research. 208. 107386–107386. 5 indexed citations
3.
Li, Yunong, et al.. (2023). Advancement of anti‐LAG ‐3 in cancer therapy. The FASEB Journal. 37(11). e23236–e23236. 14 indexed citations
4.
Li, Yunong, Lin Wang, Wei Qian, et al.. (2023). Extrachromosomal circular DNA and their roles in cancer progression. Genes & Diseases. 12(1). 101202–101202. 4 indexed citations
5.
Yan, Yuanyuan, Miao He, Lin Zhao, et al.. (2022). A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis. Cell Death and Differentiation. 29(9). 1769–1789. 63 indexed citations
6.
Jiang, Kai, Yue Fan, Lei Zhao, et al.. (2022). Screening of an annexin‐A2 ‐targeted heptapeptide for pancreatic adenocarcinoma localization. Molecular Oncology. 17(5). 872–886. 3 indexed citations
7.
Qian, Wei, Xueping Li, Mingyi Ju, et al.. (2020). Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanoma. Cancer Medicine. 9(21). 8186–8201. 18 indexed citations
8.
Wei, Minjie, et al.. (2020). Simulation and Analysis of Vibration of Hydraulic Brake System Based on Fluent. Chinese Hydraulics & Pneumatics. 158. 1 indexed citations
9.
Ju, Mingyi, Jia Bi, Qian Wei, et al.. (2020). Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Briefings in Bioinformatics. 22(4). 118 indexed citations
10.
Ju, Mingyi, Jia Bi, Lan Zhao, et al.. (2020). A five‐mRNA signature associated with post‐translational modifications can better predict recurrence and survival in cervical cancer. Journal of Cellular and Molecular Medicine. 24(11). 6283–6297. 14 indexed citations
11.
Qian, Wei, Chenyi Zhou, Mingyi Ju, et al.. (2020). Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma. International Immunopharmacology. 89(Pt A). 107162–107162. 14 indexed citations
12.
Chen, Qiuchen, Xiaolan Deng, Xiao Hu, et al.. (2019). Breast Cancer Risk–Associated SNPs in the mTOR Promoter Form De Novo KLF5- and ZEB1-Binding Sites that Influence the Cellular Response to Paclitaxel. Molecular Cancer Research. 17(11). 2244–2256. 10 indexed citations
13.
Yu, Lifeng, Xinyue Song, Jia Bi, et al.. (2019). Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death and Disease. 10(9). 666–666. 22 indexed citations
14.
Zhu, Wenjing, Miao He, Liwen Zhang, et al.. (2019). SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway. Journal of Translational Medicine. 17(1). 259–259. 46 indexed citations
15.
Jiang, Longyang, Qian Wei, Jia Bi, et al.. (2018). Identification of a novel cell cycle‐related gene signature predicting survival in patients with gastric cancer. Journal of Cellular Physiology. 234(5). 6350–6360. 58 indexed citations
16.
Ma, Mengtao, Miao He, Yan Wang, et al.. (2013). MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Letters. 339(1). 107–115. 89 indexed citations
17.
Wei, Minjie. (2012). Pharmacokinetics of Aminophylline in Rabbits. 1 indexed citations
18.
Wei, Minjie. (2011). Effect of microRNA in progressing of breast cancer and drug resistance. Zhonghua zhongliu fangzhi zazhi. 1 indexed citations
19.
Wei, Minjie. (2011). Study on Pharmacokinetics of Aminophylline in Rat. Chemistry & Bioengineering. 1 indexed citations
20.
Wei, Minjie. (2009). Vitamin E administration improves learning and memory deficits in modeling Alzheimer's disease. Zhongguo linchuang yaolixue yu zhiliaoxue. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026